Optimizing treatment in head & neck cancers - Are molecular markers the answer?

Indian Journal of Medical Research

Volumn 122, Issue 3, 2005, Pages 196-198

  D'cruz, Anil K ^a   Mulherkar, Rita ^b  

^a TATA MEMORIAL HOSPITAL   (India)

^b Research and Education in Cancer   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CELL DNA; CYCLINE; KI 67 ANTIGEN; MOLECULAR MARKER;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GRADING; CANCER INFILTRATION; CANCER INVASION; CANCER STAGING; CLINICAL TRIAL; DISEASE COURSE; GENE EXPRESSION PROFILING; HEAD AND NECK CANCER; HEAD AND NECK SURGERY; HISTOPATHOLOGY; HUMAN; HYPOPHARYNX CANCER; LARYNX CANCER; LYMPH NODE METASTASIS; MULTIMODALITY CANCER THERAPY; NOTE; PROGNOSIS; PROTEOMICS; SIDE EFFECT; TREATMENT PLANNING; TUMOR DIFFERENTIATION;

DRUG THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; RADIOTHERAPY; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 27844518789     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Note

References (9)

1. The Department of Veteran Affairs Laryngeal Cancer Study Group, Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324: 1685-90.
2. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatric A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTIC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996; 88: 890-9.
3. Pigeon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analyses of updated individual data. Lancet 2000; 355: 949-55.
4. Browman GP, Hodson DI, Mackenzie RJ, Bestic N, Zuraw L, Cancer Care Ontario Practice Guidelines Initiative Head and Neck Cancer Disease Site Group. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck 2001; 23: 579-89.
5. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greinen RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945-52.
6. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy in high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1937-44.
7. Liu M, Lawson G, Jamart J, Ide C, Coche E, Wevnand B, et al. Predictive value of the fraction of cancer cells immunolabeled for proliferating cell nuclear antigen or Ki67 in biopsies of head and neck carcinomas to identify lymph node metastasis: comparison with clinical and radiologic examinations. Head Neck 2003; 25: 280-8.
8. Byers RM, El-Naggar AK, Lee YY, Rao B, Fornage B, Terry NH, et al. Can we detect or predict the presence of occult nodal metastases in patients with squamous carcinoma of the oral tongue? Head Neck 1998; 20: 138-44.
9. Das SN, Khare P, Patil A, Pandey RM, Singh MK, Shukla NK. Association of DNA of metastatic lymphnode with disease-free survival in patients with intraoral squamous cell carcinoma. Indian J Med Res 2005; 122: 216-23.